Fireside Chat Webinar
Fireside Chat Webinar
Hosted Live | 7 Feb 2023
Bob Proulx, Imagion’s CEO, and Dr. Yalia Jayalakshmi, Chief Development Officer discussed the latest positive independent review of our MagSense® HER2 imaging agent including what this means for Imagion Biosystems; how this accelerates our path to market; an update on the future of our technology; and fielded questions from attendees in a Q&A session.
Questions? Email us: investor@imagionbio.com
Interested to learn more information about our independent review and path to market?
Read More of Our Latest News
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce
Corporate Update – IND for MagSense® HER2 Phase 2 Study Immediate Priority
Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority
Successful Placement of A$3M
Imagion Biosystems (ASX: IBX) (Company), is pleased to announce the Company has received $3 million of firm commitments through a highly successful capital raising. The
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.